Refine Results
- Applications and Industries
- Content Type
- Analysis Platform
- Language
- Publication Date
1 - 11 of 11 results
Applied Filters
必威体育登录手机This application note demonstrates the feasibility and use of combining multiple cell-based in vitro assays from Agilent that use diverse analytical technologies to investigate the cardiac liability of drugs.
This app note demonstrates the feasibility of using a connected workflow to evaluate the effect of inotropic compounds on electrically paced human iPSC derived cardiomyocytes (hiPSC-CMs) through calcium imaging
必威体育登录手机Agilent offers two instruments for assessment, drug discovery, screening, and the evaluation of cardiomyocyte models: The Agilent xCELLigence RTCA Cardio, which measures viability and contractility.必威体育登录手机The Agilent xCELLigence RTCA CardioECR, which...
必威体育登录手机This study used the Agilent xCELLigence RTCA CardioECR system with human iPSC-derived cardiomyocytes (hiPSC-CMs) to evaluate cardiac safety/toxicity of antiviral drugs.
必威体育登录手机A demonstration of the use of the Agilent xCELLigence RTCA CardioECR system to compare functional profiles of contractility and electrophysiology between an PS-iPSC-CM disease model and its isogenic control.
A technical guide to the different units that make up the xCELLigence RTCA Cardio system and its recommended E-Plate.
In this application note, the RTCA Cardio instrument is used with human stem cell-derived cardiomyocytes (iCell Cardiomyocytes) for assessment of the cardiac safety profile of leading compounds or drug candidates during drug development.
A guide for coating E-Plates.
A guide for using the xCELLigence RTCA CardioECR system to analyze iCell cardiomyocytes.
必威体育登录手机This application note presents a method for improving human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) maturation using the Agilent xCELLigence RTCA ePacer system.
In this application note, we used the xCELLigence RTCA CardioECR system (CardioECR system) in conjunction with hiPS-CMs for the assessment of preclinical cardiac risks.